Showing results (2261-2270 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|August 25, 2022
Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian RandomisationZanfina Ademi, Jedidiah I Morton, Danny Liew, et al.
Pharmacoeconomics|January 24, 2024
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United StatesAnita J Brogan, Ashley E Davis, Claire E Mellott, et al.
Pharmacoeconomics|January 24, 2024
The Burden of Type 2 Diabetes on the Productivity and Economy in Sub-Saharan Africa: A Life Table Modelling Analysis from a South African PerspectiveAssegid Hellebo, Andre P Kengne, Zanfina Ademi, et al.
Pharmacoeconomics|January 24, 2024
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic ReviewClara Marquina, Jedidiah I Morton, Melanie Lloyd, et al.
Pharmacoeconomics|August 23, 2024
Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide ModellingKurt Taylor, Nicholas R Latimer, Thomas Douglas, et al.
Pharmacoeconomics|May 31, 2024
A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility AnalysesRamesh Lamsal, E Ann Yeh, Eleanor Pullenayegum, et al.
Pharmacoeconomics|May 31, 2024
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor AnalysisMina Bahrampour, Renee Jones, Kim Dalziel, et al.
Pharmacoeconomics|May 20, 2024
A Prototype Software Framework for Transferable Computational Health Economic Models and Its Early Application in Youth Mental HealthMatthew P Hamilton, Caroline Gao, Glen Wiesner, et al.
Pharmacoeconomics|August 18, 2023
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness StudiesDeborah A Marshall, Brittany Gerber, Diane L Lorenzetti, et al.
Pharmacoeconomics|August 12, 2023
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in SwitzerlandMichaela Carla Barbier, Alicia Fengler, Esther Pardo, et al.
Pageof 336